The Immune Response to Stroke

University of Oslo1 site in 1 country40 target enrollmentJune 24, 2021

ConditionsStroke, Acute Dementia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Stroke, Acute
Sponsor: University of Oslo
Enrollment: 40
Locations: 1
Primary Endpoint: The B cell and T cell response in peripheral blood
Status: Recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Some patients develop cognitive decline after a stroke, but we don't always understand the mechanisms. It has been proposed that a proportion of the patients develop an autoimmune immune response, and that this could potentially explain the cognitive decline in some of the patients. The current study aims to investigate this hypothesis in a subgroup of patients with stroke.

Registry

clinicaltrials.gov

Start Date

June 24, 2021

End Date

June 6, 2029

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Oslo

Responsible Party

Principal Investigator

Andreas Lossius

Associate Professor

University of Oslo

Eligibility Criteria

Inclusion Criteria

•Stroke \< 72 h
•Age \> 18 years

Exclusion Criteria

•Brain hemorrhage verified by CT or MRI scan
•Previous or present immunological disease or other serious comorbidity
•Ongoing immune respons after infection or vaccination \< 1 month
•Cognitive without ability to understand and/or give an informed consent to participate in the study